/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
AbbVie or "the company" refer to AbbVie Inc., or AbbVie Inc. and its consolidated subsidiaries, as the context requires. AbbVie is a global, diversified research-based biopharmaceutical company positioned for success with a comprehensive product portfolio that has leadership positions across immunology, neuroscience, oncology and aesthetics.
$249.46
$1.36 (-0.54%)
EOD Aug 14, 2026
Margins and capital returns are both well above average: 24.65% operating margin, ROIC at 16.74%. Consistent with durable pricing power, though that alone doesn't make it a buy.
Revenue grew 8.6%, steady but not accelerating.
At 70x earnings, the current multiple leaves limited room for execution misses or growth deceleration.
70.5x earnings, 24.3x FCF. The market is pricing in years of above-average growth. If that thesis breaks, downside from multiple compression alone could be 30%+. This is a stock where you're paying for the future, not the present.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$64.39B
▲ +8.6% YoY
Net Income (TTM)
$6.31B
▼ -1.2% YoY
Op. Margin
26.20%
▲ +8.4pp YoY
ROIC
20.23%
▲ +7.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$18.21B
Op. Cash Flow (TTM)
$19.51B
▲ +1.2% YoY
Net Debt
$64.25B
Cash & Equiv.
$6.57B
5Y CAGR: +6.0%
5Y CAGR: +1.2%
Continue Research
SourceComputed from the 10-Q filed 3 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 14 Aug 2026. How this is calculated.
Price from market data, last close as of 14 Aug 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.
At a P/E of 70.5 and a price-to-free-cash-flow of 24.3, AbbVie (ABBV) trades above a two-stage DCF intrinsic value of about $141.91 per share, so at $249.46 the stock looks overvalued (43.1% above estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, AbbVie scores 42/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. It currently yields about 2.7%; see dividend safety for coverage and history. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about $141.91 per share for ABBV, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around $106.43. At today's $249.46, that puts the stock about 43.1% above estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
AbbVie scores 42 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a 26.2% operating margin and a 20.2% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Yes, AbbVie pays a regular dividend of about $6.76 per share per year (typically in quarterly installments), a yield of roughly 2.7% at the current price. That is a payout ratio of about 189.8% of earnings, so the dividend is stretched at this level. AbbVie has grown the dividend at roughly 5.9% a year over the past few years. A low headline yield is not the same as a weak dividend: what matters is how well earnings and free cash flow cover the payout and whether it is growing, not the percentage alone. For ABBV's full payout history, growth streak and dividend-safety score, see the dividends tab.
That depends on valuation and quality together, not either alone. ABBV currently trades above its estimated intrinsic value and scores 42/100 on quality (mixed). It also yields about 2.7%. A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.